bluebird bio, Inc. (BLUE)
After hours:
| Previous close | 0.5706 |
| Open | 0.5394 |
| Bid | 0.5800 x 2300 |
| Ask | 0.6023 x 8200 |
| Day's range | 0.5555 - 0.5939 |
| 52-week range | 0.5200 - 5.5300 |
| Volume | |
| Avg. volume | 7,303,485 |
| Market cap | 112.137M |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6400 |
| Earnings date | 05 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.88 |
Business Wirebluebird bio Announces September Investor Events
SOMERVILLE, Mass., August 28, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences:
Business Wirebluebird bio Announces Receipt of Expected Notices from Nasdaq
SOMERVILLE, Mass., August 23, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it received notices (the "notices") on August 20, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2024 (the "Q1 2024 Form 10-Q") and June 30, 2024 (the "Q2 2024 Form 10-Q"), it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies t
Business Wirebluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
SOMERVILLE, Mass., August 14, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported second quarter results and business highlights for the quarter ended June 30, 2024, including recent commercial and operational progress.
